MaxCyte Q1 revenue $11.6M (+78% YoY); raises 2022 core revenue guidance to at least 25%

MAXCYTE, INC.

2022-Q1 EPS reported -$0.04 revenue$11,587,300

Total revenue $11.6M, up 78% YoY; core business revenue $9.6M, up 48% YoY driven by cell therapy customers (+57%).
SPL Program-related revenue $2.0M vs immaterial; total SPLs now 16 with Intima Bioscience addition.
Net loss narrowed to $4.1M from $7.1M; EBITDA loss $3.7M vs $6.4M.
Raises 2022 core revenue guidance to at least 25% growth; reiterates SPL milestone revenue ~$4M.
Cash and investments $246.3M as of March 31, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.